TARGET 1 Price: 410.99 Profit: 12.8% (Typical rally)
Stop/Trailing Stop: 351.3 Loss: 3.6%
P/L Ratio: 3.6 : 1 - Good
POTENTIAL Excellent, there are 1 resistance areas on the way to Target 1.
Stocks may quickly rise to Targets when there are few resistance areas
4-1 Nice looking ABC to multiple supports.
As long as this issue stays above the blue and
green support lines all is well. This level also
happens to be near the 50 day SMA.
If you like these kind of chart set ups
don't forget to follow me here or on TWTR at
@AmazingPatterns
For educational and informational use only,
these are not recomendations , trade...
REGN is doing a double top and it's at the Upper Channel Resistance level, If it is not able to break this level to the upside, then it will retrace to probably the mid channel line, and eventually if market in general falls it can go to the lower channel support line. There is a negative momentum divergence, which is the signature of a downtrend.
Entry: 386,...
10-30 For those interested in buying support,
especially know considering how short term
extended things are these days. Its all about the blue line.
It also helps define ones entry risk here. If buying here
you are buying 20 points away from a support zone
(thanks anyway I say). Given this issue is tagging a
trend channel resistance zone? That is all the more...
Using a normal arithmetic scale chart, this healthcare stock has been in gradual parabolic movement until we get a Hanging Man at the top (though monthly candle for Oct is not complete yet)
Besides, the price is also at the channel top. But RSI is showing a potential bearish divergence.
I saw this weakness.
What is the chances of bull winning when this LAST bull...
It got beaten so badly because of some analyst's note saying that REGN's blockbuster eye drug Eylea has been replaced by cheaper rival drugs. First, it was only rumored to be "10%" of total patients, secondly, its rheumatoid arthritis drug "sarilumab" that is under development with Sanofi is showing promising signs and is now in phase 3. Overall, reaction is a...
Many sector leaders like Gilead, Celgene, and Biogen all had a nice run up at the end of the week, which is encouraging given people tend to sell on Friday, especially in this market.
This bad boy went berserk in April 2013, flied away from this trend line and entered into a channel, which by the way, it broke exactly one year later, April 2014. Since then...
We are at the lower boundary of the trend. Stoch sends a signal to buy. I think everything will end in complete correction yesterday's rise. In the end, is a pharmaceutical company. And now is the time to take the drugs.
